News & Research

Oprah Daily has updated its piece on AI-based breast cancer risk assessment to cover the nationwide launch of Clairity Breast through Everlywell and the NCCN guideline update on AI-powered mammogram risk assessment starting at age 35. Founder and CEO Dr. Connie Lehman and BCRF chief scientific officer Dr. Dorraya El-Ashry explain how an image-based five-year risk estimate differs from the question a mammogram answers today.

STAT examines why Clairity brought its breast cancer risk prediction directly to women rather than waiting for clinical adoption and reimbursement to catch up. The piece is part of STAT’s Paying for AI series on how new clinical AI tools affect affordability and access, and it opens on the nationwide launch with Everlywell.

Women’s Health examines the shift from age-based mammography to screening built around a woman’s individual risk, covering genetic testing, the WISDOM trial and AI tools that read risk signals from the mammogram image. Clairity Breast appears alongside them, with founder and CEO Dr. Connie Lehman on why identifying risk earlier lets clinicians find the younger women who need closer attention.

Inc. covers the nationwide availability of Clairity Breast through Everlywell and how the risk score is meant to be used. Founder and CEO Dr. Connie Lehman describes a risk estimate that can change meaningfully over time, and Everlywell CEO Julia Cheek explains why the company moved into the category.

The New York Times reports on the nationwide launch of Clairity Breast through Everlywell, which lets a woman get a five-year breast cancer risk estimate from a screening mammogram she has already had. The piece walks through how the software works, what it costs, and how clinicians are weighing risk-based screening against the limits of traditional risk models.

In a new study published in Radiology, BCRF investigator Dr. Connie Lehman, founder of Clairity Breast and professor of radiology at Harvard Medical School, and colleagues found that AI-detected signals can change over time, producing a dynamic risk score that evolves and offers insight into long-term risk.

AI is beginning to narrow a critical gap in breast cancer care. In February, Beth Israel Deaconess Medical Center (BIDMC) became the first medical center in the country to offer a new tool that uses artificial intelligence, coupled with a routine mammogram, to measure a patient’s future risk of breast cancer.

New guidelines from the National Comprehensive Cancer Network® champion artificial intelligence in breast cancer screening

Boston AI startup Clairity is providing assessments of the chance of getting breast cancer for patients at a clinic of Beth Israel Deaconess Medical Center.

Beth Israel Deaconess Medical Center (BIDMC) in Boston has administered its first clinical cancer risk score using Clairity Breast, a U.S. Food and Drug Administration (FDA)-authorized AI tool for mammogram-based breast cancer risk assessment.

Beth Israel Deaconess Medical Center on Friday rolled out an AI-driven technology that detects the risk of developing breast cancer in the next five years.